At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Saw Palmetto +1 moredrug
Likely dose
Saw Palmetto 960mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Saw Palmetto Use During Radiation Therapy for Symptom Management Among Prostate Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Saw Palmetto and soybean oil soft gel for Prostate Cancer. Completed, enrolled 48 participants across 6 sites.
Detailed Summary
The aim of this study is to test whether Saw Palmetto, is useful in preventing or reducing the side effects for men undergoing radiation therapy for prostate cancer. Urinary symptoms will be recorded each week, as well as assessment of quality of life through: 1) Physical Well-Being 2) Social/Family Well-being 3) Emotional Well-Being, and 4) Functional Well-Being.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedApr 2012
Primary CompletionApr 2015
TodayJul 2026
First PostedApr 25, 2012
Enrollment StartOct 1, 2011
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 14.2 years ago
Interventions
Saw Palmettodrug
1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
soybean oil soft geldrug
placebo (soybean oil soft gel)